C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications

migraine headaches with or without aura

Mean change from the Observation Phase in the number of migraine days per month over the entire double-blind treatment (DBT) Phase.

Proportion of subjects with ≥ 50% reduction from the Observation Phase in the number of migraine days of moderate or severe headache pain intensity per month over the entire DBT Phase (Weeks 1 to 12)., Mean change from the Observation Phase in the number of migraine days per month in the first 4 weeks (Weeks 1 to 4) of the DBT Phase., Mean change from the Observation Phase in the number of migraine days per month in the last 4 weeks (Weeks 9 to 12) of the DBT Phase., Mean change from baseline in the MSQ restrictive role function domain score at Week 12 of the DBT Phase., Mean change from baseline in the MIBS score at Week 12 of the DBT Phase.

No related papers found yet.

Austria, Belgium, Denmark, Finland, Germany, Italy, Poland, Spain, Sweden